Abstract: The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient having suffered a stroke or a transient ischemic attack, comprising the determination of the level of at least one marker peptide in said sample said marker peptide selected from the group comprising ANP, AVP, ADM, ET-1, troponin, CRP, calcitonin and hGH or fragments thereof or its precursor or fragments thereof and attributing the level of said at least one marker peptides its precursor or fragments thereof with the prognosis of an outcome or assessing the risk for said patient.
Type:
Application
Filed:
October 22, 2009
Publication date:
October 27, 2011
Applicant:
B.R.A.H.M.S. GMBH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Beat Muller
Abstract: Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab?)2, Fab or Fv) or humanized forms of such monoclonal antibodies or single chain forms (SCA; scFv) of such fragments, which antibodies, or their fragments, compete with bovine TSH for epitopes of the human TSHr, compete with autoantibodies from sera from Graves' patients as well as with autoantibodies from sera from patients harboring blocking autoantibodies for epitopes of the human TSHr, bind to conformational epitopes of the human TSHr located in the first 281 amino acids of the human TSHr, and usually also bind to TSFR receptors (TSHr) from different animals. Various uses of such antibodies, or of peptides corresponding to variable regions of such antibodies, are also described and claimed.
Type:
Grant
Filed:
June 16, 2005
Date of Patent:
October 4, 2011
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Nils G. Morgenthaler, Gilbert Vassart, Sabine Costagliola
Abstract: The present invention is concerned with an assay for detecting and/or determining the level of a protease from azurophilic granules of polymorphonuclear neutrophils or a complex thereof with an endogenous inhibitor for risk stratification and/or prognosis and/or therapy control and/or monitoring of a patient having a cardiological disease or condition.
Type:
Application
Filed:
July 3, 2009
Publication date:
September 22, 2011
Applicant:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Nils Morgenthaler, Joachim Struck, Leong Loke Ng
Abstract: The invention relates to the diagnosis of disease based on the presence of biochemical components in human or animal body fluids, tissues and/or biomaterials.
Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Grant
Filed:
September 29, 2008
Date of Patent:
August 16, 2011
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglöhner
Abstract: Disclosed is an improved sandwich immunoassay for identifying partial proANP peptides in cardiac and sepsis diagnosis by using two antibodies which specifically bond to partial sequences in the mid-regional area of NT-proANP, extending from amino acid 53 to amino acid 83 of NT-proANP.
Abstract: Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
Type:
Grant
Filed:
February 18, 2009
Date of Patent:
July 5, 2011
Assignee:
B.R.A.H.M.S. GmbH
Inventors:
Andreas Bergmann, Joachim Struck, Wolfgang Weglöhner
Abstract: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.
Abstract: Subject of the present invention is an in vitro method for the alternative assessment of peak oxygen consumption (VO2) for a subject not having a heart failure by measuring Pro-Endothelin-1 (ProET-1) or fragments thereof.
Type:
Application
Filed:
April 8, 2009
Publication date:
May 12, 2011
Applicant:
B.R.A.H.M.S Gmbh
Inventors:
Joachim Struck, Nils Morgenthaler, Andreas Bergmann, Christian Müller
Abstract: The present invention relates to an in vitro method for the diagnosis and treatment guidance of a bacterial infection in patients suffering from an acute ischemic or hemorrhagic stroke, comprising the determination of the level of Procalcitonin (PCT) or a fragment thereof having at least 12 amino acid residues in a sample of a bodily fluid from said patient and the correlation of the determined level to the diagnosis of a bacterial infection in said patient.
Type:
Application
Filed:
October 12, 2010
Publication date:
April 14, 2011
Applicant:
B.R.A.H.M.S Gmbh
Inventors:
Andreas Bergmann, Oliver Hartmann, Frauke Hein, Beat Müller
Abstract: Disclosed is a method for controlling the therapeutic treatment of a patient suffering from cardiac insufficiency. In said method, it is determined how the concentration of at least one of the vasoactive peptides adrenomedullin (ADM), endothelin-1 (ET-1), and/or vasopressin (AVP) changes in the patient's blood after beginning the therapy, and the therapeutic measures are considered to be unsatisfactory and are modified in case said concentration does not decrease at all or not enough in relation to a threshold value for the respective vasoactive peptide.